Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD38 Antibody in Pediatric Primary ITP
NCT06168851Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cm313 in immune thrombocytopenia (ITP), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Overall Response Rate at 8 weeks and Safety of Anti-CD38 antibody treatment at 5 years. Started Dec 2023; status: recruiting.
02
Drugs
cm313
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06168851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168851.